How is von Willebrand disease treated?

Treatment of Von Willebrand Disease

Treatment of von Willebrand disease is determined by disease subtype, with DDAVP as first-line for Type 1, VWF/FVIII concentrates for Type 2 (except 2B where DDAVP is contraindicated) and Type 3, and antifibrinolytics as adjunctive therapy across all types. 1

Treatment Algorithm by VWD Subtype

Type 1 VWD (70-80% of cases)

First-line therapy: DDAVP (desmopressin)

• Dose: 0.3 μg/kg IV over 20 minutes, or subcutaneous/intranasal formulations
• Mechanism: Releases stored VWF and FVIII from endothelial cells
• Expected response: 2-3 fold increase in FVIII levels, peak effect at 30-60 minutes
• Critical caveat: Test DDAVP responsiveness before relying on it for procedures 1
• Tachyphylaxis occurs after 3 consecutive doses due to storage pool depletion 1

Second-line when DDAVP fails:

• VWF-containing clotting factor concentrates (plasma-derived or recombinant)
• Administered IV to increase plasma VWF and FVIII levels
• Recombinant VWF may require concurrent recombinant FVIII administration
• Always involve hematology for product selection 1

Type 2 VWD (Qualitative Defects)

Type 2A, 2M, 2N:

• Primary treatment: Plasma-derived or recombinant VWF concentrates providing functional VWF and FVIII
• Type 2N with FVIII/VWD levels <50 IU/dL: Options include DDAVP, antifibrinolytics, or factor replacement 1

Type 2B - CRITICAL DISTINCTION:

• DDAVP is absolutely contraindicated - causes platelet clumping and consumption 1
• Treatment: VWF concentrates
• May require platelet transfusions in addition to VWF concentrates 1

Type 3 VWD (Most Severe)

Definitive treatment: Regular VWF/FVIII concentrate infusions

• Near-total absence of VWF requires consistent replacement therapy
• Symptoms include spontaneous bleeding into joints/muscles, severe mucocutaneous bleeding
• Prophylaxis regimen needed to maintain adequate VWF and FVIII levels 1

Adjunctive Therapies (All Types)

Antifibrinolytics (e.g., tranexamic acid):

• Reduce bleeding with minimal risk
• Particularly effective for mucosal bleeding and procedures with high fibrinolytic activity
• Postpartum: Continue for 2 weeks or longer after delivery 1

Hormonal therapy:

• Specifically for heavy menstrual bleeding in women
• Can be combined with other VWD-specific treatments 2, 3

Cryoprecipitate (last resort only):

• Use only when VWF/FVIII concentrates unavailable
• For Type 1 and 2A: After desmopressin failure and no concentrate availability
• For Type 2B, 2M, 2N, and 3: When specific VWF/FVIII concentrate unavailable 2

Perioperative/Procedural Management

Target levels for major surgery:

• Maintain VWF and FVIII >50 IU/dL for 5-7 days postoperatively
• Initial dose: 40-60 IU/kg VWF-containing concentrate at time of procedure, then once daily
• Combine with antifibrinolytics 1

For neuraxial anesthesia:

• VWF and FVIII levels must be >50 IU/dL before epidural placement 1

Minor procedures:

• May manage with antifibrinolytics alone in mild cases
• Consider DDAVP for Type 1 if previously responsive 1

Special Populations

Pregnancy and delivery:

• VWF levels naturally rise during pregnancy but drop rapidly postpartum
• Maintain levels >50 IU/dL for delivery
• Continue antifibrinolytics for 2 weeks postpartum minimum
• Postpartum hemorrhage risk significantly elevated 1

Women with heavy menstrual bleeding:

• Recent data shows prophylaxis with VWF/FVIII concentrates 2-3 times weekly reduces heavy menstrual bleeding by 75% compared to on-demand treatment 4
• Alternative: Tranexamic acid or hormonal therapy 5

Critical Pitfalls to Avoid

1. Never give DDAVP to Type 2B patients - causes dangerous platelet aggregation 1
2. Do not assume DDAVP works without testing - response varies significantly in Type 1 1
3. Avoid relying on aPTT alone - does not reliably predict bleeding or reflect VWF activity 1
4. Do not use cryoprecipitate when concentrates are available - inferior product with less predictable response 2
5. Factor concentrates must be prescribed by hematology - dosing and product selection require expertise 1

Emerging Therapies

Novel treatments under development include VWF aptamers (rondaptivon pegol) that reduce VWF clearance and correct platelet counts in Type 2B, and bioengineered VWF forms, though none are currently in routine clinical use 6, 7.